Abstract: The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular diseases, fibrosis (e.g. cardiac fibrosis), inflammatory or autoimmune diseases and conditions, conditions of excessive or abnormal vascularization (e.g. wound healing), stem cell differentiation and mobilization disorders, brain and neuronal dysfunctions (e.g. Alzheimer's disease, multiple sclerosis and demyelinating diseases), kidney dysfunction, renal dysfunction, preeclampsia, human immunodeficiency virus (HIV) infection and obesity. Further provided are said compounds for use in methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide, as well as for use in in vitro methods for identifying an agent useful as a therapeutic. An exemplary compound is e.g. WW-1.

Abstract: The application discloses in vitro methods for diagnosing lung cancer in a subject, wherein the method comprises detecting at least one biomarker selected from the group consisting of Rho GDP dissociation inhibitor beta (ARHGDIB), alpha-tubulin 4A (TUBA4A), glutathione S-transferase omega 1 (GSTO1), filamin A (FLNA), peroxiredoxin 6 (PRDX6) and cadherin 13 (CDH13) in a biological sample from the subject, and kits for measuring said at least one biomarker.

Abstract: The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Abstract: The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functional components and to multifunctional heteromultimeric protein complexes for directing complement-dependent cytolysis, optionally comprising a scaffold, which display three or more different functional components present in a defined relative ratio, of which one is a tracking component.

Abstract: The invention relates to a collection of signature peptides representing at least 10 proteins for use in cancer diagnosis and/or prognosis, to an artificial protein comprising signature peptides representing at least 10 proteins and to a nucleic acid construct encoding for such an artificial protein. The invention further relates to a collection of at least 10 proteins for use in cancer diagnosis and/or prognosis. Additionally, the invention relates to a method for cancer diagnosis and/or prognosis comprising the step of analyzing at least 10 proteins in a urine sample of a subject. Finally, the invention relates to an immunoassay product comprising antibodies for detecting at least 10 proteins.

Abstract: The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functional components and to multifunctional heteromultimeric protein complexes for directing complement-dependent cytolysis, optionally comprising a scaffold, which display three or more different functional components present in a defined relative ratio, of which one is a tracking component.

Abstract: The present invention relates to an inhibitor of DJ-1 (PARK7) for use in a method of treatment or prevention of immunoaging in a subject. In particular, the present invention relates to an inhibitor of DJ-1 for use in a method of treatment or prevention of an immunoaging-related disease in a subject, for use in a method of treatment or prevention of a premature aging disease in a subject, or for use in a method of treatment or prevention of vaccination inefficiency in a subject. In particular embodiments, the subject has been selected to have or has a premature aging disease, such as progeria, or the subject is an elderly subject.

Abstract: The application discloses a specific ACKR2 modulator for use in the treatment of a proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such a specific ACKR2 modulator and one or more immune checkpoint modulators, preferably one or more immune checkpoint inhibitors.

Abstract: The application discloses selective ACKR3 modulating peptides comprising amino acid sequence FGGX1MRRX2 (SEQ ID NO: 1), wherein X1 is F or W; X2 is K, V or F; and wherein the peptides have a length of at most 15 amino acids; fusion proteins comprising the peptides as taught herein; nucleic acids encoding the peptides as taught herein; nucleic acid expression cassettes and vectors comprising the nucleic acid as taught herein; and pharmaceutical compositions comprising the peptide as taught herein or the nucleic acid as taught herein. Further provided are the peptide as taught herein for use as a medicament; methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide using the peptide as taught herein; and in vitro methods for identifying an agent useful as a therapeutic using the peptide as taught herein.

Abstract: The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.

Abstract: The application discloses circRNAs as new biomarkers for the diagnosis of heart failure, the prediction of the clinical evolution of heart failure and/or prediction of the response to a treatment in a patient; methods for the prediction of outcome and diagnosis of heart failure and/or predicting the response to a treatment are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients with heart failure based on the evaluation of said one or more circRNAs.

Abstract: The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functional components and to multifunctional heteromultimeric protein complexes for directing complement-dependent cytolysis, optionally comprising a scaffold, which display three or more different functional components present in a defined relative ratio, of which one is a tracking component.

Abstract: The present invention provides a method of diagnosis or prognosis endometrial carcinoma, the method comprising determining the level of expression of MMP9 in a uterine aspirate fluid sample from the female genital tract. The present invention further provides kits for the diagnosis of the disease.

Abstract: The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.

Abstract: Provided is a method of identifying myocardially-infarcted patients having an increased risk of developing a heart condition.

Abstract: The present invention provides compositions and kits comprising miRNAs useful for the monitoring or diagnosis of heart disease in an individual. In particular, the compositions of the invention can be used for the prognosis of patients towards the development of left ventricular remodeling having suffered from an acute myocardial infarction. In addition, the present invention provides pharmaceutical compositions for the treatment of left ventricular remodeling.